High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: Implications for the treatment of non-small-cell lung cancer using 5-fluorouracil

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages

  Mochinaga, Koji ^a   Tsuchiya, Tomoshi ^a   Nagasaki, Toshiya ^a   Arai, Junichi ^a   Tominaga, Tetsuro ^a   Yamasaki, Naoya ^a   Matsumoto, Keitaro ^a   Miyazaki, Takuro ^a   Nanashima, Atsushi ^a   Hayashi, Tomayoshi ^a   Tsukamoto, Kazuhiro ^a   Nagayasu, Takeshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Adenocarcinoma in situ; Dihydropyrimidine dehydrogenase; epidermal growth factor receptor mutation; epidermal growth factor receptor tyrosine kinase inhibitor; S 1

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; WILD TYPE; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE;

EID: 84894026942     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.09.002     Document Type: Article

References (31)

1. T. Cufer, T. Ovcaricek, and M.E. O'Brien Systemic therapy of advanced non-small cell lung cancer: major developments of the last 5 years Eur J Cancer 49 2013 1216 1225
2. R. Sangha, J. Price, and C.A. Butts Adjuvant therapy in non-small cell lung cancer: current and future directions Oncologist 15 2010 862 872
3. M. Nishimura, and S. Naito Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes Drug Metab Pharmacokinet 21 2006 357 374
4. H. Kato, Y. Ichinose, and M. Ohta et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721
5. M. Nakagawa, F. Tanaka, and N. Tsubota A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathologic stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) - the 4th study Ann Oncol 16 2005 75 80
6. Y. Ichinose, K. Yoshimori, and H. Sakai et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial Clin Cancer Res 10 2004 7860 7864
7. I. Okamoto, H. Yoshioka, and S. Morita et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study J Clin Oncol 28 2010 5240 5246
8. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
9. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
10. N. Thatcher, A. Chang, and P. Parikh et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
11. H. Suehisa, S. Toyooka, and K. Hotta et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung J Clin Oncol 25 2007 3952 3957
12. T. Okabe, I. Okamoto, and S. Tsukioka et al. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase Mol Cancer Ther 7 2008 599 606
13. T. Tsuchiya, T. Nagayasu, and N. Yamasaki et al. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates Clin Lung Cancer 13 2012 464 469
14. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind International Union Against Cancer (UICC) TNM Classification of Malignant Tumors 7th ed 2009 Wiley-Blackwell Oxford, UK
15. W.D. Travis, E. Brambilla, and M. Noguchi et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
16. T. Tsuchiya, S. Hashizume, and S. Akamine et al. Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer Chest 132 2007 170 177
17. J. Arai, T. Tsuchiya, and M. Oikawa et al. Clinical and molecular analysis of synchronous double lung cancers Lung Cancer 77 2012 281 287
18. T. Nagasaki, T. Tsuchiya, and T. Tagawa et al. Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma Clin Lung Cancer 11 2010 412 422
19. K. Miyazaki, T. Shibahara, and D. Sato et al. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil- associated enzymes in human colon cancer cell lines J Gastroenterol 41 2007 140 150
20. T. Okabe, I. Okamoto, and K. Tamura et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification Cancer Res 67 2007 2046 2053
21. K. Kaira, Y. Ohde, and K. Nakagawa et al. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma Med Oncol 29 2012 1663 1672
22. G.D. Heggie, J.P. Sommadossi, and D.S. Cross et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 1987 2203 2206
23. V.A. Miller, M.G. Kris, and N. Shah et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
24. V.A. Miller, G.J. Riely, and M.F. Zakowski et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib J Clin Oncol 26 2008 1472 1478
25. P.L. Sun, H. Seol, and H.J. Lee et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features J Thorac Oncol 7 2012 323 330
26. J.L. Marks, S. Broderick, and Q. Zhou et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
27. A. Yoshizawa, S. Sumiyoshi, and M. Sonobe et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients J Thorac Oncol 8 2013 52 61
28. R. Sordella, D.W. Bell, and D.A. Haber et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
29. N. Kashima, M. Ueda, and J. Kanazawa et al. Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells Cancer Sci 94 2003 821 825
30. X. Zhang, L. Li, and J. Fourie et al. The role of Sp1 and Sp3 in the constitutive DPYD gene expression Biochim Biophys Acta 1759 2006 247 256
31. S.A. Shestopal, M.R. Johnson, and R.B. Diasio Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter Biochim Biophys Acta 1494 2000 162 169